tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

PolyPid Ltd

PYPD
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
4.290USD
-0.080-1.83%
์ข…๊ฐ€ย 07-31 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
78.10M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ
TradingKey ์ฐจํŠธ
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

-1.83%

5์ผ

+10.00%

1๊ฐœ์›”

-15.05%

6๊ฐœ์›”

-6.33%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

-1.15%

1๋…„

+25.81%

ํ•ต์‹ฌ ์ˆ˜์น˜
4.410์‹œ๊ฐ€
4.460์ตœ๊ณ ๊ฐ€
115.36K๊ฑฐ๋ž˜๋Ÿ‰
์†์‹คP/E TTM
์†์‹ค๋™์  P/E ๋น„์œจ
--๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
0.63%ํšŒ์ „์œจ
4.370์ „์ผ ์ข…๊ฐ€
4.190์ตœ์ €๊ฐ€
354.73K๋งค์ถœ์•ก
์†์‹ค์ฃผ๊ฐ€์ˆ˜์ต๋น„์œจ
7.12P/B
0.00%๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
-186.78%ROA
5.20052์ฃผ ์ตœ๊ณ ๊ฐ€
0.63๊ฑฐ๋ž˜๋Ÿ‰ ๋น„์œจ
-29.02M์ˆœ์ด์ต
18.20M์ฃผ์‹
-1.7385์ฃผ๋‹น์ˆœ์ด์ต
1.43๋ฒ ํƒ€
-758.61%ROE
2.44052์ฃผ ์ตœ์ €๊ฐ€
6.18%๋ณ€๋™ ํญ
--์ด ์ด์ต๋ฅ 
78.10M์‹œ๊ฐ€์ด์•ก
-6.52๋ณด์ƒ/์œ„ํ—˜
3.33%์œ„ํ—˜๋ฅ 

PolyPid Ltd ๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์˜ˆ์ƒ๎˜

์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€

4 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
12.000
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+194.12%
์ƒ์Šน ์—ฌ๋ ฅ
๊ฐ•๋ ฅ ๋งค์ˆ˜
๋งค์ˆ˜
์œ ์ง€
๋งค๋„
๊ฐ•๋ ฅ ๋งค๋„

๋™์ข…์—…๊ณ„ ๋น„๊ต

160
์ด๊ณ„
6
์ค‘๊ฐ„
9
ํ‰๊ท 
ํšŒ์‚ฌ ์ด๋ฆ„
ํ‰๊ฐ€
๋ถ„์„๊ฐ€
PolyPid Ltd
PYPD
4
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32

์ง€ํ‘œ๎˜

์ง€ํ‘œ
๋งค๋„(3)
์ค‘๋ฆฝ(2)
๋งค์ˆ˜(1)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MACD(12,26,9)
-0.129
๋งค๋„
RSI(14)
45.584
์ค‘๋ฆฝ
STOCH(KDJ)(9,3,3)
40.131
๋งค์ˆ˜
ATR(14)
0.461
๊ณ ๋ณ€๋™์„ฑ
CCI(14)
-23.932
์ค‘๋ฆฝ
Williams %R
69.231
๋งค๋„
TRIX(12,20)
-0.796
๋งค๋„
StochRSI(14)
89.695
๊ณผ๋งค๋„
์ด๋™ ํ‰๊ท 
๋งค๋„(4)
์ค‘๋ฆฝ(0)
๋งค์ˆ˜(2)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MA5
4.094
๋งค์ˆ˜
MA10
4.150
๋งค์ˆ˜
MA20
4.722
๋งค๋„
MA50
4.761
๋งค๋„
MA100
4.591
๋งค๋„
MA200
4.338
๋งค๋„

์žฌ๋ฌด ์ง€ํ‘œ๎˜

EPS

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ด ์ˆ˜์ต

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

PolyPid Ltd ์ •๋ณด๎˜

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
์ข…๋ชฉ ์ฝ”๋“œ PYPD
ํšŒ์‚ฌPolyPid Ltd
CEOAkselbrad (Dikla Czaczkes)
์›น์‚ฌ์ดํŠธhttps://www.polypid.com

์ฃผ์ฃผ๎˜

์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Aurum Ventures M.K.I.
18.60%
Hodges (Rodney)
10.71%
Centaurus Investments Limited
5.80%
AIGH Capital Management, LLC.
5.31%
Rosalind Advisors, Inc.
3.65%
๊ธฐํƒ€
55.92%

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

PolyPid Ltd(PYPD)์˜ ํ˜„์žฌ ๊ฐ€๊ฒฉ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
PolyPid Ltd(PYPD)์˜ ํ˜„์žฌ ์ฃผ๊ฐ€๋Š” 4.29์ž…๋‹ˆ๋‹ค.

PolyPid Ltd์˜ ์ข…๋ชฉ ๊ธฐํ˜ธ(Symbol)๋Š” ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
PolyPid Ltd์˜ ์ข…๋ชฉ ์ฝ”๋“œ๋Š” PYPD์ž…๋‹ˆ๋‹ค.

PolyPid Ltd์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
PolyPid Ltd์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” 5.20์ž…๋‹ˆ๋‹ค.

PolyPid Ltd์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
PolyPid Ltd์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” 2.44์ž…๋‹ˆ๋‹ค.

PolyPid Ltd์˜ ์‹œ๊ฐ€์ด์•ก์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
PolyPid Ltd์˜ ์‹œ๊ฐ€์ด์•ก์€ 78.10M์ž…๋‹ˆ๋‹ค.

PolyPid Ltd(PYPD)์˜ ํ˜„์žฌ ํˆฌ์ž ๋“ฑ๊ธ‰์€ ๋งค์ˆ˜, ๋ณด์œ , ๋งค๋„ ์ค‘ ์–ด๋–ค๊ฐ€์š”?

๎™Œ
์• ๋„๋ฆฌ์ŠคํŠธ๋“ค์— ๋”ฐ๋ฅด๋ฉด, PolyPid Ltd(PYPD)๋Š” ์ „๋ฐ˜์ ์ธ ํ‰๊ฐ€์—์„œ ๊ตฌ์ž…ํ•˜๋‹ค ๋“ฑ๊ธ‰์„ ๋ฐ›๊ณ  ์žˆ์œผ๋ฉฐ, ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” 12.00์ž…๋‹ˆ๋‹ค.

PolyPid Ltd(PYPD)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
PolyPid Ltd(PYPD)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ -2.09์ž…๋‹ˆ๋‹ค.
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ